PET for radiation treatment planning of brain tumours.

AA-PET (MET-PET and FET-PET) can be used for gross tumour volume (GTV) delineation in brain gliomas and for the differentiation between treatment-related changes (pseudo-progression, pseudo-regression) and residual/recurrent tumour. There are some data showing that MET-PET and (DOTATOC)-PET can be used for GTV delineation in meningiomas and glomus tumours. The role of PET in the visualization of the biological characteristics of the tumours: proliferation (FLT-PET), hypoxia (FMISO-PET) and angiogenesis/peptide expression (RGD-PET) should be investigated in future studies.

[1]  Branislav Jeremic,et al.  L-(methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy. , 2005, International journal of radiation oncology, biology, physics.

[2]  M. Schwaiger,et al.  Effect of 11C-methionine-positron emission tomography on gross tumor volume delineation in stereotactic radiotherapy of skull base meningiomas. , 2008, International journal of radiation oncology, biology, physics.

[3]  Peter Kneschaurek,et al.  Validation of a method for automatic image fusion of CT-data and C11-methionin-PET data for stereotactic radiotherapy using a LINAC (BrainLAB System). First clinical results , 2002 .

[4]  Yue Cao,et al.  Association of 11C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme. , 2009, International journal of radiation oncology, biology, physics.

[5]  M. Schwaiger,et al.  Correlation Between Postoperative 3-[123I]Iodo-l-α-Methyltyrosine Uptake and Survival in Patients with Gliomas , 2001 .

[6]  M Schwaiger,et al.  The value of F-18-fluorodeoxyglucose PET for the 3-D radiation treatment planning of malignant gliomas. , 1998, International journal of radiation oncology, biology, physics.

[7]  Wolfgang A Weber,et al.  11C-methionine PET improves the target volume delineation of meningiomas treated with stereotactic fractionated radiotherapy. , 2006, International journal of radiation oncology, biology, physics.

[8]  Klaus Wienhard,et al.  Glioma Proliferation as Assessed by 3‘-Fluoro-3’-Deoxy-l-Thymidine Positron Emission Tomography in Patients with Newly Diagnosed High-Grade Glioma , 2008, Clinical Cancer Research.

[9]  M. Schwaiger,et al.  Implications of IMT-SPECT for postoperative radiotherapy planning in patients with gliomas. , 2002, International journal of radiation oncology, biology, physics.

[10]  M Schwaiger,et al.  First experience with I-123-alpha-methyl-tyrosine spect in the 3-D radiation treatment planning of brain gliomas. , 2000, International journal of radiation oncology, biology, physics.

[11]  Jean Charles Gilbert,et al.  Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  Morand Piert,et al.  Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. , 2004, International journal of radiation oncology, biology, physics.

[13]  K. Zilles,et al.  Comparison of fluorotyrosines and methionine uptake in F98 rat gliomas. , 2003, Nuclear medicine and biology.

[14]  Peter Kneschaurek,et al.  Validation of a method for automatic image fusion (BrainLAB System) of CT data and 11C-methionine-PET data for stereotactic radiotherapy using a LINAC: first clinical experience. , 2003, International journal of radiation oncology, biology, physics.

[15]  Wolfgang A Weber,et al.  Technology Insight: advances in molecular imaging and an appraisal of PET/CT scanning , 2008, Nature Clinical Practice Oncology.

[16]  Markus Schwaiger,et al.  [18F]Galacto-RGD Positron Emission Tomography for Imaging of αvβ3 Expression on the Neovasculature in Patients with Squamous Cell Carcinoma of the Head and Neck , 2007, Clinical Cancer Research.

[17]  Y. Matsuzaki,et al.  Dynamics of delayed p53 mutations in mice given whole-body irradiation at 8 weeks. , 2011, International journal of radiation oncology, biology, physics.

[18]  C. Belka,et al.  [68Ga]-DOTATOC-PET/CT for meningioma IMRT treatment planning , 2009, Radiation oncology.

[19]  Wolfgang A. Weber,et al.  O-(2-[18F]Fluoroethyl)-l-tyrosine and l-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study , 2000, European Journal of Nuclear Medicine.

[20]  Wolfgang A Weber,et al.  An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases. , 2011, International journal of radiation oncology, biology, physics.

[21]  M. Schwaiger,et al.  Assessment of tumor volumes in skull base glomus tumors using Gluc-Lys[(18)F]-TOCA positron emission tomography. , 2009, International journal of radiation oncology, biology, physics.

[22]  O. Ratib,et al.  Recurrence pattern after [(18)F]fluoroethyltyrosine-positron emission tomography-guided radiotherapy for high-grade glioma: a prospective study. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[23]  Dieta Brandsma,et al.  Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. , 2008, The Lancet. Oncology.

[24]  U. Haberkorn,et al.  Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOC-PET. , 2006, International journal of radiation oncology, biology, physics.